GLI transcription factors: Mediators of oncogenic Hedgehog signalling

2006 ◽  
Vol 42 (4) ◽  
pp. 437-445 ◽  
Author(s):  
Maria Kasper ◽  
Gerhard Regl ◽  
Anna-Maria Frischauf ◽  
Fritz Aberger
2015 ◽  
Vol 11 (8) ◽  
pp. 2190-2197 ◽  
Author(s):  
Wolfgang Schmidt-Heck ◽  
Madlen Matz-Soja ◽  
Susanne Aleithe ◽  
Eugenia Marbach ◽  
Reinhard Guthke ◽  
...  

The Hedgehog signalling-driven Gli transcription factors in hepatocytes form a regulatory network identified by a fuzzy-logic modelling approach. The network explains dynamic features important for hepatocyte function and fate.


Pneumologie ◽  
2018 ◽  
Vol 72 (S 01) ◽  
pp. S114-S115
Author(s):  
M Wygrecka ◽  
M Didiasova ◽  
R Singh ◽  
J Wilhelm ◽  
G Kwapiszewska ◽  
...  

Pancreatology ◽  
2013 ◽  
Vol 13 (2) ◽  
pp. e25
Author(s):  
M.G. Fernandez-Barrena ◽  
L.L. Almada ◽  
M.E. Fernandez-Zapico

Author(s):  
Yang Yue ◽  
Martin F. Engelke ◽  
T. Lynne Blasius ◽  
Kristen J. Verhey

The kinesin-4 motor KIF7 is a conserved regulator of the Hedgehog signaling pathway. In vertebrates, Hedgehog signaling requires the primary cilium, and KIF7 and Gli transcription factors accumulate at the cilium tip in response to Hedgehog activation. Unlike conventional kinesins, KIF7 is an immotile kinesin and its mechanism of ciliary accumulation is unknown. We generated KIF7 variants with altered microtubule binding or motility. We demonstrate that microtubule binding of KIF7 is not required for the increase in KIF7 or Gli localization at the cilium tip in response to Hedgehog signaling. In addition, we show that the immotile behavior of KIF7 is required to prevent ciliary localization of Gli transcription factors in the absence of Hedgehog signaling. Using an engineered kinesin-2 motor that enables acute inhibition of intraflagellar transport (IFT), we demonstrate that kinesin-2 KIF3A/KIF3B/KAP mediates the translocation of KIF7 to the cilium tip in response to Hedgehog pathway activation. Together, these results suggest that KIF7’s role at the tip of the cilium is unrelated to its ability to bind to microtubules.


2016 ◽  
Vol 291 (49) ◽  
pp. 25749-25760 ◽  
Author(s):  
Meng Wu ◽  
Lishann Ingram ◽  
Ezequiel J. Tolosa ◽  
Renzo E. Vera ◽  
Qianjin Li ◽  
...  

2010 ◽  
Vol 6 (8) ◽  
pp. e1000908 ◽  
Author(s):  
Thomas C. Whisenant ◽  
David T. Ho ◽  
Ryan W. Benz ◽  
Jeffrey S. Rogers ◽  
Robyn M. Kaake ◽  
...  

2021 ◽  
Vol 22 (19) ◽  
pp. 10670
Author(s):  
Fabian Freisleben ◽  
Franziska Modemann ◽  
Jana Muschhammer ◽  
Hauke Stamm ◽  
Franziska Brauneck ◽  
...  

The prognosis of elderly AML patients is still poor due to chemotherapy resistance. The Hedgehog (HH) pathway is important for leukemic transformation because of aberrant activation of GLI transcription factors. MBZ is a well-tolerated anthelmintic that exhibits strong antitumor effects. Herein, we show that MBZ induced strong, dose-dependent anti-leukemic effects on AML cells, including the sensitization of AML cells to chemotherapy with cytarabine. MBZ strongly reduced intracellular protein levels of GLI1/GLI2 transcription factors. Consequently, MBZ reduced the GLI promoter activity as observed in luciferase-based reporter assays in AML cell lines. Further analysis revealed that MBZ mediates its anti-leukemic effects by promoting the proteasomal degradation of GLI transcription factors via inhibition of HSP70/90 chaperone activity. Extensive molecular dynamics simulations were performed on the MBZ-HSP90 complex, showing a stable binding interaction at the ATP binding site. Importantly, two patients with refractory AML were treated with MBZ in an off-label setting and MBZ effectively reduced the GLI signaling activity in a modified plasma inhibitory assay, resulting in a decrease in peripheral blood blast counts in one patient. Our data prove that MBZ is an effective GLI inhibitor that should be evaluated in combination to conventional chemotherapy in the clinical setting.


Sign in / Sign up

Export Citation Format

Share Document